Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis

Thrombosis Research

Volumn 115, Issue 1-2, 2005, Pages 3-8

  Crowther, Mark A ^a   Wisloff, Finn ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiphospholipid antibodies; Thromboembolism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL PRACTICE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; LITERATURE; MEDLINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; THROMBOSIS; TREATMENT OUTCOME; WARFARIN;

EID: 9644270402     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.041     Document Type: Review

References (18)

1. S. Schulman, E. Svenungsson, and S. Granqvist Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group Am. J. Med. 104 4 1998 332 338
2. C. Kearon, M. Gent, J. Hirsh, J.I. Weitz, M.J. Kovacs, and D. Anderson A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N. Engl. J. Med. 340 12 1999 901 907
3. H.I. Brunner, W.S. Chan, J.S. Ginsberg, and B.M. Feldman Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. Result of a decision analysis J. Rheumatol. 29 3 2002 490 501
4. M. Petri Management of thrombosis in antiphospholipid antibody syndrome Rheum. Dis. Clin. North Am. 27 3 2001 633 642
5. J. Hirsh, J. Dalen, D.R. Anderson, L. Poller, H. Bussey, and J. Ansell Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 119 1 Suppl. 2001 8S 21S
6. M.A. Khamashta, M.J. Cuadrado, F. Mujic, N.A. Taub, B.J. Hunt, and G.R. Hughes The management of thrombosis in the antiphospholipid-antibody syndrome N. Engl. J. Med. 332 1995 993 997
7. M.H. Rosove, and P.M. Brewer Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients Ann. Intern. Med. 117 1992 303 308
8. M.A. Crowther, J.S. Ginsberg, M. Gent, J. Julian, L. Costantini, and M.J. Kovacs A randomized trial of two intensities of warfarin (international normalized ratio of 2.0 to 3.0 versus 3.1 to 4.0) for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies N. Engl. J. Med. 349 2003 1133 1138
9. G. Finazzi, R. Marchioli, and T. Barbui A randomized clinical trial of oral anticoagulant therapy in patients with antiphospholipid antibody syndrome: the WAPS study J. Thromb. Haemost. 1 s1 2003 OC365
10. A. Oden, and M. Fahlen Oral anticoagulation and risk of death: a medical record linkage study BMJ 325 7372 2002 1073 1075
11. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells PS, Julian J, et al. Comparison of one month with three months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. Submitted to Annals of Internal Medicine. 2003.
12. Kearon C, Ginsberg JS, Kovacs MJ, Anderson D, Wells PS, Julian J, et al. Low-intensity (INR 1.5-1.9) versus conventional-intensity (INR 2.0-3.0) anticoagulation for extended treatment of unprovoked VTE: a randomized double blind trial. Blood 100[11(s1)], 150a (Abs 562). 2002.
13. S.R. Levine, R.L. Brey, B.C. Tilley, J.L. Thompson, R.L. Sacco, and R.R. Sciacca Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke JAMA 291 5 2004 576 584
14. J.P. Mohr, J. Thompson, R.M. Lazar, B. Levin, R.L. Sacco, and K.L. Furie A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke N. Engl. J. Med. 345 20 2002 1444 1451
15. G. Simonneau, H. Sors, B. Charbonnier, Y. Page, J.P. Laaban, and R. Azarian A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism N. Engl. J. Med. 337 1997 663 669
16. R.F. van Es, J.J. Jonker, F.W. Verheugt, J.W. Deckers, and D.E. Grobbee Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial Lancet 360 9327 2002 109 113
17. M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen Warfarin, aspirin, or both after myocardial infarction [see comment, summary for patients in CMAJ. 2002 Oct 29;167(9):1036; PMID: 12403748] N. Engl. J. Med. 347 13 2002 969 974
18. J.S. Levine, D.W. Branch, and J. Rauch The antiphospholipid syndrome N. Engl. J. Med. 346 10 2002 752 763